Literature DB >> 2215576

The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease.

A B Chapman1, A Johnson, P A Gabow, R W Schrier.   

Abstract

BACKGROUND: A high incidence of hypertension (50 to 75 percent) occurs early in the course of autosomal dominant polycystic kidney disease. Cyst enlargement, causing bilateral renal ischemia and subsequent release of renin, is proposed as the cause of this form of hypertension.
METHODS: To investigate this hypothesis, we measured plasma renin activity and aldosterone concentrations during short-term and long-term converting-enzyme inhibition in 14 patients with hypertension due to polycystic kidney disease, 9 patients with essential hypertension, 11 normotensive patients with polycystic kidney disease, and 13 normal subjects. The groups were comparable with respect to age, sex, body-surface area, degree of hypertension, sodium excretion, and renal function.
RESULTS: During the short-term study, the mean (+/- SE) plasma renin activity was significantly higher in the hypertensive patients with polycystic kidney disease than in the patients with essential hypertension, in the supine (0.36 +/- 0.06 vs. 0.22 +/- 0.06 ng per liter.second, P = 0.05) and upright positions (1.03 +/- 0.14 vs. 0.61 +/- 0.08 ng per liter.second, P less than 0.03) and after converting-enzyme inhibition (1.97 +/- 0.28 vs. 0.67 +/- 0.17 ng per liter.second, P less than 0.0006). The mean arterial pressures measured in the supine and upright positions and the plasma aldosterone concentrations measured in the upright position were significantly higher in the normotensive patients with polycystic kidney disease than in the normal subjects. After six weeks of converting-enzyme inhibition, renal plasma flow increased (P less than 0.005), and both renal vascular resistance (P less than 0.007) and the filtration fraction (P less than 0.02) decreased significantly in the hypertensive patients with polycystic kidney disease but not in the patients with essential hypertension.
CONCLUSIONS: The renin-angiotensin-aldosterone system is stimulated significantly more in hypertensive patients with polycystic kidney disease than in comparable patients with essential hypertension. The increased renin release, perhaps due to renal ischemia caused by cyst expansion, probably contributes to the early development of hypertension in polycystic kidney disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2215576     DOI: 10.1056/NEJM199010183231602

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  84 in total

1.  Hypertension in Autosomal Dominant Polycystic Kidney Disease: A Clinical and Basic Science Perspective.

Authors:  Shobha Ratnam; Surya M Nauli
Journal:  Int J Nephrol Urol       Date:  2010

2.  Angiotensin blockade in late autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Kaleab Z Abebe; Arlene B Chapman; Robert W Schrier; William E Braun; Theodore I Steinman; Franz T Winklhofer; Godela Brosnahan; Peter G Czarnecki; Marie C Hogan; Dana C Miskulin; Frederic F Rahbari-Oskoui; Jared J Grantham; Peter C Harris; Michael F Flessner; Charity G Moore; Ronald D Perrone
Journal:  N Engl J Med       Date:  2014-11-15       Impact factor: 91.245

3.  Blood pressure in early autosomal dominant polycystic kidney disease.

Authors:  Robert W Schrier; Kaleab Z Abebe; Ronald D Perrone; Vicente E Torres; William E Braun; Theodore I Steinman; Franz T Winklhofer; Godela Brosnahan; Peter G Czarnecki; Marie C Hogan; Dana C Miskulin; Frederic F Rahbari-Oskoui; Jared J Grantham; Peter C Harris; Michael F Flessner; Kyongtae T Bae; Charity G Moore; Arlene B Chapman
Journal:  N Engl J Med       Date:  2014-11-15       Impact factor: 91.245

4.  Transport, cilia, and PKD: must we in (cyst) on interrelationships? Focus on "Increased Na+/H+ exchanger activity on the apical surface of a cilium-deficient cortical collecting duct principal cell model of polycystic kidney disease".

Authors:  Ellis D Avner; Alicia A McDonough; William E Sweeney
Journal:  Am J Physiol Cell Physiol       Date:  2012-03-07       Impact factor: 4.249

5.  Blood pressure and survival in long-term hemodialysis patients with and without polycystic kidney disease.

Authors:  Miklos Z Molnar; Lilia R Lukowsky; Elani Streja; Ramanath Dukkipati; Jennie Jing; Allen R Nissenson; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  J Hypertens       Date:  2010-12       Impact factor: 4.844

6.  Mineralocorticoid Antagonism and Vascular Function in Early Autosomal Dominant Polycystic Kidney Disease: A Randomized Controlled Trial.

Authors:  Kristen L Nowak; Berenice Gitomer; Heather Farmer-Bailey; Wei Wang; Mikaela Malaczewski; Jelena Klawitter; Zhiying You; Diana George; Nayana Patel; Anna Jovanovich; Michel Chonchol
Journal:  Am J Kidney Dis       Date:  2019-02-23       Impact factor: 8.860

Review 7.  Potential pharmacological interventions in polycystic kidney disease.

Authors:  Amirali Masoumi; Berenice Reed-Gitomer; Catherine Kelleher; Robert W Schrier
Journal:  Drugs       Date:  2007       Impact factor: 9.546

8.  Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease.

Authors:  Imed Helal; Kim McFann; Berenice Reed; Xiang-Dong Yan; Robert W Schrier; Godela M Fick-Brosnahan
Journal:  Nephrol Dial Transplant       Date:  2012-12-04       Impact factor: 5.992

9.  The HALT polycystic kidney disease trials: design and implementation.

Authors:  Arlene B Chapman; Vicente E Torres; Ronald D Perrone; Theodore I Steinman; Kyongtae T Bae; J Philip Miller; Dana C Miskulin; Frederic Rahbari Oskoui; Amirali Masoumi; Marie C Hogan; Franz T Winklhofer; William Braun; Paul A Thompson; Catherine M Meyers; Cass Kelleher; Robert W Schrier
Journal:  Clin J Am Soc Nephrol       Date:  2010-01       Impact factor: 8.237

Review 10.  Heterotrimeric G protein signaling in polycystic kidney disease.

Authors:  Taketsugu Hama; Frank Park
Journal:  Physiol Genomics       Date:  2016-05-13       Impact factor: 3.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.